Trial Profile
A phase 2 efficacy and safety study of SU011248 [sunitinib] in patients with metastatic non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Oct 2008 Checked against ClinicalTrials.gov record - last updated 15 Oct 2008.
- 14 Mar 2008 Status changed from in progress to completed on ClinicalTrials.gov
- 03 Jan 2008 The expected completion date for this trial is now 1 Mar 2007.